GlassScriptPhysician profile
Jane K James
NPI 1104468040
$1,093.13
in general payments reported to CMS, 2019-2025
19 companies · $749 in 2025
The $749 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.53 · 2024: $331 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $278.71 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $156.46 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.83 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $73.81 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.20 | 2024 | Synjardy, Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $57.55 | 2024-2025 | Breztri, Airsupra |
| Abbott Laboratories | $56.22 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $45.82 | 2025 | Verquvo, Capvaxive |
| Phathom Pharmaceuticals, INC. | $36.87 | 2025 | Voquezna |
| Pfizer INC. | $33.64 | 2025 | |
| Corcept Therapeutics | $33.19 | 2025 | Korlym |
| Abbvie INC. | $32.96 | 2025 | |
| Novartis Pharmaceuticals Corporation | $27.10 | 2025 | |
| Sumitomo Pharma America, INC. | $21.29 | 2025 | Gemtesa |
| Bridgebio Pharma, INC. | $20.44 | 2025 | Attruby |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $19.06 | 2025 | Fluad, Flucelvax |
| Alnylam Pharmaceuticals INC. | $18.97 | 2025 | Onpattro |
| Amgen INC. | $17.48 | 2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $13.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.